<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="638">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04355247</url>
  </required_header>
  <id_info>
    <org_study_id>CCAM 20-01</org_study_id>
    <nct_id>NCT04355247</nct_id>
  </id_info>
  <brief_title>Prophylactic Corticosteroid to Prevent COVID-19 Cytokine Storm</brief_title>
  <official_title>Prophylactic Corticosteroid to Prevent COVID-19 Cytokine Storm</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Auxilio Mutuo Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Auxilio Mutuo Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase II pilot exploratory study designed to investigate if prophylactic treatment
      with short term steroids administered to high risk Covid-19 patient might prevent cytokine
      storm and progression to respiratory failure. High risk is defined based on serologic markers
      of inflammation that include abnormalities of Interleukin 6 (IL-6), Ferritin , D-dimer,
      Lactate Dehydrogenase (LDH), as well as lymphopenia and impaired O2 saturation prior to or on
      the 7th day of first symptom of Covid-19.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To decrease the rate of progression to hypoxemic respiratory failure in high risk patients
      with Covid-19, treated with prophylactic steroids during the first phase of the disease.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 14, 2020</start_date>
  <completion_date type="Anticipated">April 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This is a pilot Phase II exploratory study. It is a non-randomized study which will be carried out at Auxilio Mutuo Hospital and possibly at other institutions to be recruited.
The investigator plans to enter a total of 20 patients in order to determine whether the risk of progressing to respiratory failure can be reduced by administering corticosteroids.
The investigator assume that virtually all patients who met the criteria for entry into this trial will develop respiratory insufficiency if left untreated.
If &lt;/= 50% of patients with high risk develop respiratory failure the investigator will consider the treatment as successful.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical complete response criteria</measure>
    <time_frame>14 days</time_frame>
    <description>Clinical complete response criteria requires all the following:
No need for ventilatory support at any point
O2 Saturation of &gt;/= 93% by day 14 of therapy
Alive by day 28 from registration
CT chest with minimal or no evidence of disease by day 28 from registration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Partial Response criteria</measure>
    <time_frame>14 days</time_frame>
    <description>Clinical Partial Response criteria require that 2 of the following be present by day 14 of therapy:
No need for ventilatory support at any point O2 saturation &gt; 93% bay day 14 from registration
CT chest stable to improve over baseline by day 28 from registration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary response criteria</measure>
    <time_frame>14 days</time_frame>
    <description>Decrease of at least 25% in anyone of the following markers: IL-6, Ferritin, D-dimer, C reactive protein (CRP) or LDH by day 14
- Improvement of absolute lymphocyte count in those presenting with lymphopenia. Improvement is defined as increase by 25% or more by day 14.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Covid-19</condition>
  <arm_group>
    <arm_group_label>Single Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be admitted to a regular room in the hospital (not ICU)
They will be monitored closely with vital signs every 4 hours to ensure their respiratory and cardiovascular status do not deteriorate.
Methylprednisolone 80 mg IV bolus injection will be given daily x 5 days starting upon day 1 of admission to hospital.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MethylPREDNISolone 80 Mg/mL Injectable Suspension</intervention_name>
    <description>Patients will be admitted to a regular room in the hospital (not ICU)
They will be monitored closely with vital signs every 4 hours to ensure their respiratory and cardiovascular status do not deteriorate.
Methylprednisolone 80 mg IV bolus injection will be given daily x 5 days starting upon day 1 of admission to hospital.</description>
    <arm_group_label>Single Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients diagnosed with Covid-19 will be registered on the study regardless pf
             their severity, but only those who meet high risk criteria will be treated with
             steroids. Those who don't meet the criteria will only be registered with no need to
             collect further data except baseline labs and CT Chest. They should sign the consent
             form and the data manager can collect the rest of the information.

          -  Patients older than 18 years diagnosed with Covid-19 by Polymerase Chain Reaction
             (PCR) or by rapid serological test will be eligible. Cases who are Immunoglobulin G
             (IgG) positive but Immunoglobulin M (IgM) negative, will not be considered eligible
             unless they are positive for molecular PCR test. Eligible patients will be registered
             on study on or before 7 days from first onset of symptoms.

        Exclusion Criteria:

          -  Any patient with life expectancy &lt; 1 month

          -  Any patient who is oxygen dependent

          -  Any patient with long standing history of severe Chronic Obstructive Pulmonary Disease
             (COPD)

          -  Any patient who is chronically oxygen dependent because of previous existing lung
             disease

          -  Anyone with severely uncontrolled diabetes despite adequate management

          -  Anyone with active serious bacterial infection such as septicemia or pneumonia

          -  Anyone receiving Tocilizumab (anti IL-6 therapy) or plasma therapy

          -  Any patient already receiving steroids from another pre-existing illness
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fernando Cabanillas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Español Auxilio Mutuo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fernando Cabanillas, MD</last_name>
    <phone>787-758-2000</phone>
    <phone_ext>3503</phone_ext>
    <email>cabanillasmd@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Idalia Liboy, MD</last_name>
    <phone>787-758-2000</phone>
    <phone_ext>3569</phone_ext>
    <email>iliboy@auxiliomutuo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>San Juan City Hospital / Puerto Rico Medical Center</name>
      <address>
        <city>San Juan</city>
        <zip>00917</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmelo Santana-López, MD</last_name>
      <phone>787-480-2700</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Auxilio Mutuo Cancer Center</name>
      <address>
        <city>San Juan</city>
        <zip>00918</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fernando Cabanillas, MD</last_name>
      <phone>787-758-2000</phone>
      <phone_ext>3513</phone_ext>
      <email>cabanillasmd@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Idalia Liboy, MD</last_name>
      <phone>787-758-2000</phone>
      <phone_ext>3569</phone_ext>
      <email>iliboy@auxiliomutuo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Fernando Cabanillas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carmelo Santana-López, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>James Bryan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Juan Arraut, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>José Abreu-Arbelo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luis Cotto, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mirelis Acosta-Rivera, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Margarita Bruno, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Idalia Liboy, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
  </location_countries>
  <link>
    <url>https://www.medrxiv.org/content/10.1101/2020.03.01.20029769v2</url>
    <description>The potential role of IL-6 in monitoring severe case of coronavirus disease 2019</description>
  </link>
  <link>
    <url>https://www.medrxiv.org/content/10.1101/2020.04.01.20047381v2</url>
    <description>Level of IL-6 predicts respiratory failure in hospitalized symptomatic COVID-19 patients</description>
  </link>
  <reference>
    <citation>Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, Doudier B, Courjon J, Giordanengo V, Vieira VE, Tissot Dupont H, Honoré S, Colson P, Chabrière E, La Scola B, Rolain JM, Brouqui P, Raoult D. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020 Jul;56(1):105949. doi: 10.1016/j.ijantimicag.2020.105949. Epub 2020 Mar 20.</citation>
    <PMID>32205204</PMID>
  </reference>
  <reference>
    <citation>Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis. 2020 Apr;20(4):398-400. doi: 10.1016/S1473-3099(20)30141-9. Epub 2020 Feb 27.</citation>
    <PMID>32113510</PMID>
  </reference>
  <reference>
    <citation>Carr AC. A new clinical trial to test high-dose vitamin C in patients with COVID-19. Crit Care. 2020 Apr 7;24(1):133. doi: 10.1186/s13054-020-02851-4.</citation>
    <PMID>32264963</PMID>
  </reference>
  <reference>
    <citation>Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11. Erratum in: Lancet. 2020 Mar 28;395(10229):1038. Lancet. 2020 Mar 28;395(10229):1038.</citation>
    <PMID>32171076</PMID>
  </reference>
  <reference>
    <citation>Zhang C, Wu Z, Li JW, Zhao H, Wang GQ. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. Int J Antimicrob Agents. 2020 May;55(5):105954. doi: 10.1016/j.ijantimicag.2020.105954. Epub 2020 Mar 29.</citation>
    <PMID>32234467</PMID>
  </reference>
  <reference>
    <citation>Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, Huang H, Zhang L, Zhou X, Du C, Zhang Y, Song J, Wang S, Chao Y, Yang Z, Xu J, Zhou X, Chen D, Xiong W, Xu L, Zhou F, Jiang J, Bai C, Zheng J, Song Y. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. 2020 Jul 1;180(7):934-943. doi: 10.1001/jamainternmed.2020.0994.</citation>
    <PMID>32167524</PMID>
  </reference>
  <reference>
    <citation>Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020 Feb 15;395(10223):473-475. doi: 10.1016/S0140-6736(20)30317-2. Epub 2020 Feb 7.</citation>
    <PMID>32043983</PMID>
  </reference>
  <reference>
    <citation>Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, Feldt T, Green G, Green ML, Lescure FX, Nicastri E, Oda R, Yo K, Quiros-Roldan E, Studemeister A, Redinski J, Ahmed S, Bernett J, Chelliah D, Chen D, Chihara S, Cohen SH, Cunningham J, D'Arminio Monforte A, Ismail S, Kato H, Lapadula G, L'Her E, Maeno T, Majumder S, Massari M, Mora-Rillo M, Mutoh Y, Nguyen D, Verweij E, Zoufaly A, Osinusi AO, DeZure A, Zhao Y, Zhong L, Chokkalingam A, Elboudwarej E, Telep L, Timbs L, Henne I, Sellers S, Cao H, Tan SK, Winterbourne L, Desai P, Mera R, Gaggar A, Myers RP, Brainard DM, Childs R, Flanigan T. Compassionate Use of Remdesivir for Patients with Severe Covid-19. N Engl J Med. 2020 Jun 11;382(24):2327-2336. doi: 10.1056/NEJMoa2007016. Epub 2020 Apr 10.</citation>
    <PMID>32275812</PMID>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 17, 2020</study_first_submitted>
  <study_first_submitted_qc>April 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2020</study_first_posted>
  <last_update_submitted>April 17, 2020</last_update_submitted>
  <last_update_submitted_qc>April 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Auxilio Mutuo Cancer Center</investigator_affiliation>
    <investigator_full_name>Fernando Cabanillas</investigator_full_name>
    <investigator_title>Medicine Doctor/Medical Director</investigator_title>
  </responsible_party>
  <keyword>Severe Acute Respiratory Syndrome (SARS)-Cov-2 Virus</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Acetate</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

